

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT4328655

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
L'ASSISTANCE-PUBLIQUE HOPITAUX DE PARIS	02/10/2016
RECEIVING PARTY DATA	
Name:	NLS-1 PHARMA AG
Street Address:	BREITENWEG 10
City:	STANS
State/Country:	SWITZERLAND
Postal Code:	CH-6370
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	13980708
CORRESPONDENCE DATA	
Fax Number:	(610)640-7835
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	610-640-7820
Email:	bwdocket@pepperlaw.com
Correspondent Name:	DANIEL M. SCOLNICK
Address Line 1:	PEPPER HAMILTON LLP
Address Line 2:	899 CASSATT ROAD
Address Line 4:	BERWYN, PENNSYLVANIA 19312
ATTORNEY DOCKET NUMBER:	135702.02611
NAME OF SUBMITTER:	MELISSA SEEBARAN
SIGNATURE:	/Melissa Seebaran/
DATE SIGNED:	03/21/2017
Total Attachments: 6	
source=Assignment_Patent_Transfer_Agreement_L'Assistance_Publique_to_NLS-1_Pharma_AG#page1.tif	
source=Assignment_Patent_Transfer_Agreement_L'Assistance_Publique_to_NLS-1_Pharma_AG#page2.tif	
source=Assignment_Patent_Transfer_Agreement_L'Assistance_Publique_to_NLS-1_Pharma_AG#page3.tif	
source=Assignment_Patent_Transfer_Agreement_L'Assistance_Publique_to_NLS-1_Pharma_AG#page4.tif	
source=Assignment_Patent_Transfer_Agreement_L'Assistance_Publique_to_NLS-1_Pharma_AG#page5.tif	

EXTRACTS

PATENT TRANSFER AGREEMENT

No. VAL 15/03-031/05-058/10-159/11-181/03

BETWEEN:

L'ASSISTANCE PUBLIQUE – HOPITAUX DE PARIS, a public administrative institution with head office at 3 avenue Victoria, 75001 Paris, represented by its Managing Director, Martin HIRSCH and by delegation Ms Florence Favrel-Feuillade, Director of the Clinical Research and Development Department

Hereinafter "AP-HP",

"The Transferors"

ON THE ONE HAND

AND:

NLS-1 Pharma AG, a limited joint stock company with share capital of 100,000 Swiss francs, identified in the Trade Register for the Canton of Nidwald, Switzerland, under No. CHE-447.067.367, having its head office at Breitenweg 10, 6370 Stanss, represented by Ronald Hafner, Chairman, and Alexander Zwyer, CEO

Hereinafter "NLS" or "NLS-1 Pharma AG" or the "Transferee",

ON THE OTHER HAND,

AP-HP and NLS being jointly designated hereinafter as the "Parties".

1
NLS
FFP

PATENT

REEL: 042050 FRAME: 0792

[...]

THEREFORE, IT HAS BEEN AGREED AND DECIDED AS FOLLOWS:

PRELIMINARY ARTICLE - DEFINITIONS

PATENTS means:

1 - "Use of iron for treating attention deficit hyperactivity disorder in children" (WO2004105744 - Priority date: 30 May 2003)

↓

Alh

F.B.F.

2. "Mazindol combination in the treatment of attention deficit/hyperactivity" (WO2007116076 - Priority date: 11 April 2006)
3. "Lauflumide and the enantiomers thereof, method for preparing same and therapeutic uses thereof" (WO2012098235 - Priority date: 20 January 2011)
4. "Phacetoperane for the treatment of attention-deficit hyperactivity disorder" (WO2013079873 - Priority date: 29 November 2011).

[...]

ARTICLE 1 - SUBJECT OF THE AGREEMENT

- 1.1 The Transferors mentioned above transfer to NLS, that accepts, the priority right and all of the ownership and enjoyment rights on the PATENTS, as well as on the Know-How relating thereto. This sale is granted and accepted for all countries covered by the PATENTS without limitation to application of the PATENTS.
- 1.2 Consequently, NLS becomes the owner of the PATENTS and has full and entire enjoyment thereof from the time of AP-HP's effective receipt of the sums indicated in Article 3.

[...]

↓
NLS
FFF

ARTICLE 3 - FINANCIAL CONDITIONS

3.1 The Transferors agree to sell the PATENTS to the Transferee, that duly accepts, for a sum of [---] before tax.

[---]

1
ne
ffz

ARTICLE 6 - ENTRY INTO FORCE

This agreement shall enter into force on the last signature date thereof.

[...]

ARTICLE 8 - APPLICABLE LAW

The French version of the Agreement is the binding one. The Agreement is governed by French law.

The Parties shall make every effort to resolve any disputes arising on the interpretation or performance of the Agreement amicably. Should their disagreement persist, the Paris Courts shall be solely competent to judge the dispute.

↓
Alu
FFF

ARTICLE 9 - REGISTRATION

The Transferee shall proceed with all necessary registrations in the national patent register and/or in foreign and international patent registers.


APPENDIX 1: INVENTORS' CONSENT

Produced in 2 originals

For AP-HP

Signed in Paris,
on _____

Florence Favrel-Feuillade
Director of the Clinical Research and Development
Department



François Rain

Financial Controller
Le Contrôleur Financier

21 JAN. 2016

For NLS



Roland Hafner



Alexander Zwyer

In Paris,
on _____

EMPEGANGEN 10. Feb. 2016



NLS Pharma
Connecting Brains

NLS Pharma Group
Breitenweg 10
CH-6970 Stans

